Award Date

1-1-2007

Degree Type

Thesis

Degree Name

Master of Science (MS)

Department

Chemistry

First Committee Member

Stephen W. Carper

Number of Pages

111

Abstract

The antitumor agent that is most prescribed for the treatment of cancer is cis-diamminedichloroplatinum (II) (cisplatin), but its application is limited due to toxic side effects; especially nephrotoxicity. Due to these limitations, numerous analogs have been developed. The cytotoxicity of five novel cisplatin analogs, dichloro(4,4'-diethyl-2,2'-bipyridine)platinum, dichloro(4,4'-dipropyl-2,2'-bipyridine)platinum, dichloro(4,4'-di-t-butyl-2,2'-bipyridine)platinum, dichloro(4,4'-dimethoxy-2,2'-bipyridine)platinum and dichloro[4,4'-bis(3-methoxypropyl)-2,2'-bipyridine]platinum, in lung (A549), prostate (DU-145) and five breast (MCF-7, MDA-MB-435, MDA-MB-231, DC4 and DB46) cancer cell lines were investigated. Clonogenic survivals demonstrated that these novel analogs were 47 to 242 times more lethal than cisplatin and killed cells predominately by apoptosis. The analogs did not typically cause a block in the cell cycle. Results from clonogenic survivals and calculation of the combination index (CI) revealed that several analogs had slightly synergistic interactions with ionizing radiation to kill prostate and breast cancer cell lines. Results indicate that these novel analogs may be potential antitumor agents in clinical treatment.

Keywords

Analogs; Breast; Cancer; Cells; Cisplatin; Cytotoxicity; Lung; Novel; Prostate

Controlled Subject

Biochemistry; Pharmacology

File Format

pdf

File Size

2836.48 KB

Degree Grantor

University of Nevada, Las Vegas

Language

English

Permissions

If you are the rightful copyright holder of this dissertation or thesis and wish to have the full text removed from Digital Scholarship@UNLV, please submit a request to digitalscholarship@unlv.edu and include clear identification of the work, preferably with URL.

Identifier

https://doi.org/10.25669/fys6-5g60


Share

COinS